Patent · US Active

Protein vaccines against poxviruses

US7790182B2 · kind B2 · utility

5Cited by

5References

14Claims

0Family size

Assignee

The United States of America as represented by the Secretary of the Army · US

Inventors

Jay Hooper · New Market, US
Genoveffa Franchini · Washington, US

Key dates

Filing date	Sep 20, 2006
Grant date	Sep 7, 2010
Priority date	—
Expiry date	Mar 16, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/24134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.